Aspirin - Substance Summary (SID: 476106)
The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
  Table of Contents
 Drug and Chemical Information: (Total:5)
Display: Previous 1 | Next 1 | All
kavain
RN given refers to cpd without isomeric designation; see also kavaform; structure
Anticonvulsants
- Anti-inflammatory agents that are not steroids. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and ... Anticonvulsants
- Anti-inflammatory agents that are not steroids. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They are used primarily in the treatment of chronic arthritic conditions and certain soft tissue disorders associated with pain and inflammation. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Certain NSAIDs also may inhibit lipoxygenase enzymes or TYPE C PHOSPHOLIPASES or may modulate T-cell function. (AMA Drug Evaluations Annual, 1994, p 1814-5)  | Anti-Anxiety Agents
- Fibrinolysin or agents that convert plasminogen to fibrinolysin (PLASMIN). |
Pharmacological ClassificationSafety and Toxicology
EINECS - European Inventory of Existing Commercial Chemical Substances | TOXLINE - Citations to the toxicological literature |
 Literature Literature Keyword Mining Tool
 Data Source: 
Depositor: DTP/NCIExternal ID: 406186
 BioActivity Results:
Tested in BioAssays: All: 6 Inactive: 6
BioActivity Summary: This Substance with Similar Substances
AID: 175 Source: DTP/NCI
NCI Yeast Anticancer Drug Screen. Data for the mlh1 rad18 strain
AID: 167 Source: DTP/NCI
NCI Yeast Anticancer Drug Screen. Data for the bub3 strain
AID: 165 Source: DTP/NCI
NCI Yeast Anticancer Drug Screen. Data for the cln2 rad14 strain
AID: 161 Source: DTP/NCI
NCI Yeast Anticancer Drug Screen. Data for the sgs1 mgt1 strain
|
more ...
 Properties Computed from Structure:
| Molecular Weight | 180.15742 [g/mol] | | Molecular Formula | C9H8O4 | | H-Bond Donor | 1 | | H-Bond Acceptor | 4 | | Rotatable Bond Count | 3 | | Exact Mass | 180.042259 | | MonoIsotopic Mass | 180.042259 | | Topological Polar Surface Area | 63.6 | | Heavy Atom Count | 13 | | Formal Charge | 0 | | Complexity | 212 | | Isotope Atom Count | 0 | | Defined Atom StereoCenter Count | 0 | | Undefined Atom StereoCenter Count | 0 | | Defined Bond StereoCenter Count | 0 | | Undefined Bond StereoCenter Count | 0 | | Covalently-Bonded Unit Count | 1 |
Descriptors Computed from Structure:
IUPAC Name: 2-acetyloxybenzoic acid
Canonical SMILES: CC(=O)OC1=CC=CC=C1C(=O)O
Substance Information:
Depositor-Supplied Comments:
DTP/NCI from molfile. Release-June 2007.
Structure Evaluation:Consistent with Molecular Formula.
Deposition record created from database webdb on host dtpiv1.ncifcrf.gov on Feb 22, 2008
|
|
|
| Compound ID | 2244 |
| | Molecular Weight | 180.15742 [g/mol] |
| | Molecular Formula | C9H8O4 |
| | H-Bond Donor | 1 |
| | H-Bond Acceptor | 4 |
|
 Links |
